Change 5-day change 1-year change 3-year change Capi.($)
+28.60%-18.62% - - 16.15M
+3.31%-3.70%+61.03%+103.64% 70.42B
+1.09%+2.51%+49.34%+93.39% 65.4B
-1.03%+0.46%+8.14%-5.28% 28.28B
-2.41%-2.95%-9.77%+455.82% 27.16B
0.00%-1.37%+62.05%+11.16% 26.57B
+1.02%+6.43%+269.42%+420.34% 20.61B
+0.37%+1.21%+36.55%-15.78% 20.09B
-2.00%-4.74%+12.89%+528.83% 15.87B
-1.50%+2.92%+43.50%+151.30% 13.9B
Average +2.68%+1.37%+59.24%+193.71% 32.03B
Weighted average by Cap. +0.59%+0.94%+56.31%+155.32%
Logo Opexa Therapeutics Inc
Acer Therapeutics Inc. is a pharmaceutical company, which is focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
Employees
-